近日，复星医药旗下复星万邦销售的复泽霖®利丙双卡因乳膏在阿里健康首发。该产品是一种外用表面 麻醉剂，适用于皮肤穿刺及浅层外科手术前的镇痛，已在全球范围内拥有长期应用历史。此次合作，标 志着复星医药进一步拓展院外市场，携手阿里健康共同为消费者提供更便捷、专业、合规的镇痛解决方 案。 作为国家药品监督管理局批准用于皮肤穿刺及浅层外科手术镇痛的处方药，利丙双卡因乳膏自1998年在 中国上市以来，一直是临床基础麻醉的重要选择。 然而，随着医美、男科等消费医疗场景的蓬勃发展，该产品在院外市场的应用也迅速显性化，在男科领 域，它被《早泄诊断与治疗指南》列为一线推荐方案；在蓬勃发展的轻医美市场(如光电项目、微针、 注射等)，它则成为术前镇痛的合规首选。 伴随政策规范的逐步完善与用户需求的日益凸显，复星医药积极推动该产品走向更广阔的市场。此次选 择与阿里健康合作，正是基于作为"新特药首发阵地"在数字化健康服务方面的平台优势，旨在更直接地 触达注重隐私、便捷与安全的消费者。 近年来，利丙双卡因乳膏在公立医院及消费医疗市场均呈现稳步增长。根据微信公众号邴药说的测算， 利丙双卡因乳膏国内市场持续向上增长，2024年利丙双卡因乳膏在 ...

Group 1: Company Strategy and Market Focus - In 2026, the company will focus on stabilizing its existing business and driving innovation through a dual approach, emphasizing both hospital and external markets [2][3] - Key products in the external market include Loxoprofen Sodium Gel Patch, Ketoprofen Gel Patch, and other newly acquired exclusive varieties [4] - The company aims to enhance brand recognition and terminal coverage through the new "JiuDian Pain Relief" brand image [2] Group 2: Innovation and Product Development - The company will continue to adopt a strategy of "independent research and project introduction" for innovative drugs, actively seeking competitive projects [5] - Plans to enrich the product pipeline through collaborative research and development, as well as industry-academia transformation [5] Group 3: Financial Outlook and Shareholder Returns - The company will develop a scientific and sustainable shareholder return plan over the next 2-3 years based on operational performance and market conditions [8] - There is a potential for further acquisitions to enhance the product line and business layout as needed [8] Group 4: Market Challenges and Pricing Impact - The implementation of centralized procurement for Loxoprofen Sodium Gel Patch may lead to a temporary decrease in gross margin due to price adjustments [7] - The company will maintain a stable overseas business primarily focused on the export of raw materials and pharmaceutical excipients [6]